Literature DB >> 23121699

[Diabetic retinopathy screening and teleophthalmology].

M Martínez Rubio1, M Moya Moya, A Bellot Bernabé, J Belmonte Martínez.   

Abstract

OBJECTIVE: To determine the prevalence of diabetic retinopathy (DR) and evaluate our experience in DR screening in a study carried out between the Ophthalmology Department of the University General Hospital of Alicante and Department 19 Primary Care of Alicante by using a non-retinal mydriatic camera and telemedicine.
MATERIAL AND METHODS: A descriptive, cross-sectional study was conducted on 2,435 diabetic patients from 1 February 2006 to 1 February 2009. Three 45° retinographies of both eyes of each patient were obtained and sent to the Department of Ophthalmology via the hospital intranet. These were then evaluated by 2 ophthalmologists, experts in the retina, with each issuing an individualized report for each patient.
RESULTS: The prevalence of DR was 17.90%, with 80.73% of them having mild-moderate proliferative DR, 12.16% severe non-proliferative DR, 2.29% proliferative DR, and 4.82% with diabetic maculopathy associated with any level of retinopathy. The retinographies were considered low quality in 41 patients (1.69%).
CONCLUSIONS: We highlight the benefits of the tele-ophthalmology in screening diabetic patients to enable early diagnosis and treatment, and improving the circuit of communication between primary and specialist care.
Copyright © 2011 Sociedad Española de Oftalmología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23121699     DOI: 10.1016/j.oftal.2012.04.004

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  9 in total

1.  Outcome of universal newborn eye screening with wide-field digital retinal image acquisition system: a pilot study.

Authors:  P Goyal; T R Padhi; T Das; L Pradhan; S Sutar; S Butola; U C Behera; L Jain; S Jalali
Journal:  Eye (Lond)       Date:  2017-07-24       Impact factor: 3.775

Review 2.  A systematic review of teleophthalmological studies in Europe.

Authors:  Georgios Labiris; Eirini-Kanella Panagiotopoulou; Vassilios P Kozobolis
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

Review 3.  The empirical evidence for the telemedicine intervention in diabetes management.

Authors:  Rashid L Bashshur; Gary W Shannon; Brian R Smith; Maria A Woodward
Journal:  Telemed J E Health       Date:  2015-03-25       Impact factor: 3.536

4.  Structural Changes by Spectral Domain Optical Coherence Tomography in Patients With Type 1 Diabetes Mellitus.

Authors:  Nicole Mendez; Sumana S Kommana; Bernard Szirth; Albert S Khouri
Journal:  J Diabetes Sci Technol       Date:  2015-08-31

Review 5.  Teleophthalmology: improving patient outcomes?

Authors:  Omana Kesary Sreelatha; Sathyamangalam VenkataSubbu Ramesh
Journal:  Clin Ophthalmol       Date:  2016-02-10

6.  [Prevalence and risk factors associated with diabetic retinopathy in Santander. Northern Spain].

Authors:  José María Castillo-Otí; Joaquín Cañal-Villanueva; María Teresa García-Unzueta; Ana Isabel Galván-Manso; María Rosa Callejas-Herrero; Pedro Muñoz-Cacho
Journal:  Aten Primaria       Date:  2019-05-17       Impact factor: 1.137

Review 7.  Changes in the Epidemiology of Diabetic Retinopathy in Spain: A Systematic Review and Meta-Analysis.

Authors:  Pedro Romero-Aroca; Maribel López-Galvez; Maria Asuncion Martinez-Brocca; Alicia Pareja-Ríos; Sara Artola; Josep Franch-Nadal; Joan Fernandez-Ballart; José Andonegui; Marc Baget-Bernaldiz
Journal:  Healthcare (Basel)       Date:  2022-07-16

8.  Retinal diseases in a reference center from a Western Amazon capital city.

Authors:  Fernando Korn Malerbi; Nilson Hideo Matsudo; Adriano Biondi Monteiro Carneiro; Claudio Luiz Lottenberg
Journal:  Einstein (Sao Paulo)       Date:  2015 Oct-Dec

9.  Implementation of a diabetic retinopathy referral network, Peru.

Authors:  Omar Salamanca; Amelia Geary; Nancy Suárez; Sara Benavent; Merly Gonzalez
Journal:  Bull World Health Organ       Date:  2018-08-27       Impact factor: 9.408

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.